ALK Inhibitor Crystal Form for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing crystal forms of the anaplastic lymphoma kinase inhibitor compound of formula (1) lack optimal properties for solubility, stability, and bioavailability, which are crucial for effective drug development and treatment of ALK-mediated diseases.
Innovation Solution
Development of two distinct crystal forms, A and B, characterized by specific X-ray powder diffraction patterns and thermal analysis profiles, along with a controlled preparation method involving solvent selection, temperature gradients, and seed crystal addition for enhanced purity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing crystal forms are used, then the drug can be produced, but the solubility, stability, and bioavailability are not optimal for effective treatment
Solution Approach 1:
The patent applies parameter changes by identifying and characterizing different crystal forms (polymorphs) of the ALK inhibitor compound. Each crystal form has distinct X-ray powder diffraction patterns, melting points, and physical properties. By changing the crystalline state parameters, the patent achieves optimal solubility, stability, and bioavailability for treatment effectiveness while maintaining compositional stability through well-defined crystal structures.
2Reliability
If new crystal forms are developed to improve solubility and bioavailability, then treatment effectiveness improves, but the complexity of characterization and quality control increases
Solution Approach 1:
The patent uses characteristic X-ray powder diffraction patterns as 'fingerprint' identifiers for each crystal form. Each polymorph exhibits distinct diffraction peak patterns at specific 2θ angles, enabling straightforward characterization and quality control. This approach simplifies the detection and identification process, making it easier to distinguish between different crystal forms and ensure consistent product quality.
Solution Approach 2:
The patent replaces complex biological activity assays with physical characterization methods (X-ray diffraction, DSC, TGA) to identify and differentiate crystal forms. This substitution of mechanical/physical measurement systems for biological testing simplifies the characterization process while providing reliable, reproducible data for quality control and bioavailability assessment.
3Adaptability or versatility
If multiple crystal forms are produced, then optimal properties for different applications can be achieved, but the manufacturing process becomes more complex
Solution Approach 1:
The patent employs parameter changes through controlled crystallization conditions (solvent type, temperature, pH, additives) to selectively produce different crystal forms. By adjusting these parameters during the manufacturing process, the patent can target specific polymorphs with desired properties for different formulation needs, maintaining ease of manufacture through well-established crystallization techniques.
Solution Approach 2:
The patent applies preliminary action by using seed crystals of the desired crystal form to guide the crystallization process. By introducing pre-formed seeds of the target polymorph early in the crystallization process, the patent ensures selective formation of the desired crystal form, simplifying manufacturing by avoiding the need to develop and optimize complex multi-step purification processes for each polymorph.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new crystal forms exhibit improved solubility, stability, and bioavailability, facilitating effective treatment and prevention of ALK-mediated diseases, including various cancers, with ease of industrial production and quality control.
Implementation Method 1
the activity of the intracellular kinase region of ALK and the corresponding signaling pathway are important molecular mechanisms leading to the formation of ALKCL. After ALK, ROS1 is currently a relatively hot target gene studied in lung adenocarcinoma. ROS1 is a member of the receptor tyrosine kinase family
Implementation Method 2
characterized by an X-ray powder diffraction pattern comprising characteristic peaks at 11.9±0.2°, 14.0±0.2°, 15.2±0.2°, 17.2±0.2°, 17.5±0.2°, and 21.5±0.2° expressed as 2θ angles using Cu-Kα radiation
Implementation Method 3
an X-ray powder diffraction pattern comprising characteristic peaks at 11.9±0.2°, 14.0±0.2°, 15.2±0.2°, 17.2±0.2°, 17.5±0.2°, and 21.5±0.2° expressed as 2θ angles
Implementation Method 4
characterized by a differential scanning calorimetry analysis diagram comprising an endothermic peak in the range of about 190°C to 205°C
Implementation Method 5
characterized by a thermogravimetric analysis wherein the crystal form B has no weight loss at 250°C or less
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to a crystal form of a polycyclic anaplastic lymphoma kinase inhibitor and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and use of the crystal form or the pharmaceutical composition. Specifically, the present invention relates to a crystal form of a compound, i.e., 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(7-methyl-8-(piperidin-4-yl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)pyrimidine-2,4-diamine, that is represented by formula (1) and serves as an anaplastic lymphoma kinase inhibitor, a preparation method therefor, a pharmaceutical composition comprising the crystal form, and the use of the crystal form or the pharmaceutical composition in a medication for preventing and/or treating an anaplastic lymphoma kinase-mediated cancer or a non-cancer related disease.